FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361885738> ?p ?o ?g. }

• W4361885738 abstract "<p>Synergy of dasatinib and anti-CTLA-4. Using murine GIST mouse, it was observed that treatment with the KIT-targeted dasatinib for 7 days alone or with chronic anti-CTLA-4 alone decreased tumor volume initially; however tumors rapidly re-grew. Mice treated with KIT-targeted TKI for 7 days and chronic anti-CTLA-4 blockade showed augmentation and durability of the initial response. KITV5880+ mice received dasatinib 15mg/kg i.p. bid (Bristol Myers Squibb) on days 1 through 7, with or without anti-CTLA-5 (BioXcell.) Mice were imaged at baseline and serially during therapy using MRI and volumetric analysis was done using Image K software. Anti-CTLA-4 dosing regimen 200 microgram of clone 9H10 i.p. on day 3, then 100 microgram on day 6, 9 and 12, followed by clone 9D (100 micrograms i.p. every 3 days thereafter.)</p>" @default.
• W4361885738 created "2023-04-05" @default.
• W4361885738 creator A5006374965 @default.
• W4361885738 creator A5012215691 @default.
• W4361885738 creator A5018352846 @default.
• W4361885738 creator A5021264035 @default.
• W4361885738 creator A5021772683 @default.
• W4361885738 creator A5030608642 @default.
• W4361885738 creator A5031037291 @default.
• W4361885738 creator A5034595315 @default.
• W4361885738 creator A5040291209 @default.
• W4361885738 creator A5041435283 @default.
• W4361885738 creator A5043833554 @default.
• W4361885738 creator A5045094375 @default.
• W4361885738 creator A5045240203 @default.
• W4361885738 creator A5067158281 @default.
• W4361885738 creator A5082874698 @default.
• W4361885738 creator A5086473468 @default.
• W4361885738 creator A5086786876 @default.
• W4361885738 creator A5089731384 @default.
• W4361885738 creator A5090065800 @default.
• W4361885738 creator A5090809833 @default.
• W4361885738 date "2023-03-31" @default.
• W4361885738 modified "2023-09-23" @default.
• W4361885738 title "Supplemental Figure 1 from Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab" @default.
• W4361885738 doi "https://doi.org/10.1158/1078-0432.22463484" @default.
• W4361885738 hasPublicationYear "2023" @default.
• W4361885738 type Work @default.
• W4361885738 citedByCount "0" @default.
• W4361885738 crossrefType "posted-content" @default.
• W4361885738 hasAuthorship W4361885738A5006374965 @default.
• W4361885738 hasAuthorship W4361885738A5012215691 @default.
• W4361885738 hasAuthorship W4361885738A5018352846 @default.
• W4361885738 hasAuthorship W4361885738A5021264035 @default.
• W4361885738 hasAuthorship W4361885738A5021772683 @default.
• W4361885738 hasAuthorship W4361885738A5030608642 @default.
• W4361885738 hasAuthorship W4361885738A5031037291 @default.
• W4361885738 hasAuthorship W4361885738A5034595315 @default.
• W4361885738 hasAuthorship W4361885738A5040291209 @default.
• W4361885738 hasAuthorship W4361885738A5041435283 @default.
• W4361885738 hasAuthorship W4361885738A5043833554 @default.
• W4361885738 hasAuthorship W4361885738A5045094375 @default.
• W4361885738 hasAuthorship W4361885738A5045240203 @default.
• W4361885738 hasAuthorship W4361885738A5067158281 @default.
• W4361885738 hasAuthorship W4361885738A5082874698 @default.
• W4361885738 hasAuthorship W4361885738A5086473468 @default.
• W4361885738 hasAuthorship W4361885738A5086786876 @default.
• W4361885738 hasAuthorship W4361885738A5089731384 @default.
• W4361885738 hasAuthorship W4361885738A5090065800 @default.
• W4361885738 hasAuthorship W4361885738A5090809833 @default.
• W4361885738 hasBestOaLocation W43618857381 @default.
• W4361885738 hasConcept C121608353 @default.
• W4361885738 hasConcept C126322002 @default.
• W4361885738 hasConcept C142424586 @default.
• W4361885738 hasConcept C143998085 @default.
• W4361885738 hasConcept C16930146 @default.
• W4361885738 hasConcept C170493617 @default.
• W4361885738 hasConcept C185592680 @default.
• W4361885738 hasConcept C2775922572 @default.
• W4361885738 hasConcept C2777701055 @default.
• W4361885738 hasConcept C2778468042 @default.
• W4361885738 hasConcept C2779536868 @default.
• W4361885738 hasConcept C2781413609 @default.
• W4361885738 hasConcept C2781433595 @default.
• W4361885738 hasConcept C42362537 @default.
• W4361885738 hasConcept C552990157 @default.
• W4361885738 hasConcept C55493867 @default.
• W4361885738 hasConcept C71924100 @default.
• W4361885738 hasConcept C81089528 @default.
• W4361885738 hasConcept C86803240 @default.
• W4361885738 hasConcept C87355193 @default.
• W4361885738 hasConcept C90924648 @default.
• W4361885738 hasConceptScore W4361885738C121608353 @default.
• W4361885738 hasConceptScore W4361885738C126322002 @default.
• W4361885738 hasConceptScore W4361885738C142424586 @default.
• W4361885738 hasConceptScore W4361885738C143998085 @default.
• W4361885738 hasConceptScore W4361885738C16930146 @default.
• W4361885738 hasConceptScore W4361885738C170493617 @default.
• W4361885738 hasConceptScore W4361885738C185592680 @default.
• W4361885738 hasConceptScore W4361885738C2775922572 @default.
• W4361885738 hasConceptScore W4361885738C2777701055 @default.
• W4361885738 hasConceptScore W4361885738C2778468042 @default.
• W4361885738 hasConceptScore W4361885738C2779536868 @default.
• W4361885738 hasConceptScore W4361885738C2781413609 @default.
• W4361885738 hasConceptScore W4361885738C2781433595 @default.
• W4361885738 hasConceptScore W4361885738C42362537 @default.
• W4361885738 hasConceptScore W4361885738C552990157 @default.
• W4361885738 hasConceptScore W4361885738C55493867 @default.
• W4361885738 hasConceptScore W4361885738C71924100 @default.
• W4361885738 hasConceptScore W4361885738C81089528 @default.
• W4361885738 hasConceptScore W4361885738C86803240 @default.
• W4361885738 hasConceptScore W4361885738C87355193 @default.
• W4361885738 hasConceptScore W4361885738C90924648 @default.
• W4361885738 hasLocation W43618857381 @default.
• W4361885738 hasLocation W43618857382 @default.
• W4361885738 hasOpenAccess W4361885738 @default.
• W4361885738 hasPrimaryLocation W43618857381 @default.
• W4361885738 hasRelatedWork W2046134042 @default.
• W4361885738 hasRelatedWork W2566021721 @default.
• W4361885738 hasRelatedWork W2603638259 @default.

• next